Skip to content
The BCI Briefing

Company profileCore BCI

BCIFlex

A Beijing company with an implanted wireless BCI in a registered study for tetraplegia.

Location
Beijing, China
Founded
2022
Class
Core BCI
Also known as
BCIFlex Medical Technology Co., Ltd.
Funding stage
Series A
Sources last checked
6 Oct 2026

What they are building

Beijing company founded in 2022. It describes its system as invasive and fully implanted, with stretchable, flexible electrodes and 560 to 1,024 channels, and launched it at the Zhongguancun Forum in March 2026. A study at Beijing Tiantan Hospital in people with tetraplegia from cervical spinal cord injury is recruiting.

Invasiveness
Invasive
Recording / stimulation
Recording
Main use cases
Move, Control
Works with
Beijing Tiantan Hospital

Where they are clinically

Clinical study

A larger structured study of safety and performance, short of a pivotal trial.

Trade press reports a first implantation in 2025 at a hospital of Jilin University. The registry lists one study: 34 participants planned at Beijing Tiantan Hospital, recruiting since July 2026. Neither says whether the electrodes sit on or in the brain, and no result has been published.

Access today

Clinical study

Accessible only by enrolling in a registered clinical study.

Shown in people
A first implantation in 2025, reported by trade press without results. One registered study is recruiting.
Still an aim
Assisted grasp after cervical spinal cord injury.
What stands in the way
A public record: no result, paper or registry outcome yet.

On record here: 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

BCIFlex joins Neuracle, StairMed and NeuroXess, each with a registered implant study of 32 to 34 participants in China, and it targets the use Neuracle's NEO is registered for: assisted grasp after cervical spinal cord injury. What is public is a registry entry and trade-press reports of a launch, a funding round and a first implantation; no result is.

Key milestones

  1. 15 Jul 2026

    A study of the implantable wireless system in tetraplegia begins recruiting at Beijing Tiantan Hospital; 34 participants planned.

    ClinicalTrials.gov

  2. 31 Mar 2026

    Launches a fully implanted system with stretchable, flexible electrodes and up to 1,024 channels at the Zhongguancun Forum in Beijing.

    VCBeat

  3. 12 Aug 2025

    Series A of more than RMB 300 million ($42M) reported, led by Zhongguancun Independent Innovation Fund, Legend Capital and YuanBio Venture Capital.

    G-MedTech

  4. 2025

    First clinical implantation, at a hospital of Jilin University, as reported by trade press.

    VCBeat

Funding history

  • 12 Aug 2025≈ $42MSeries A · led by Zhongguancun Independent Innovation Fund, Legend Capital, YuanBio Venture CapitalReported as more than RMB 300 million; the dollar figure is the report's.Reported by trade press.

Investors namedZhongguancun Independent Innovation Fund · Legend Capital · YuanBio Venture Capital

Rounds in the Briefing’s sample only; not a complete funding history.

IP and patents

Filings touch 5 of the 11 layers, most often interface and electrodes (22 of 24 families) and surgical access (11).

24
patent families identified and counted as BCI
2022
earliest first filing among them
24
first filed since 2021; the latest years are incomplete
22 of 24
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (22), insertion tools and robots (10), peripheral interfaces (10), stimulation (6), implant electronics (5), packaging and hermeticity (5). A family can carry several.

Published in: China (24), United States (8), counted over the 24 families whose full record was read.

Representative families

18 more families counted

Families found for BCIFlex in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Sources

  1. 01

    ClinicalTrials.gov NCT07784088: Implantable wireless brain-computer interface systems in patients with tetraplegia (opens in a new tab)

    Clinical registryClinicalTrials.govChecked against source 5 Oct 2026

    Sponsor BCIFlex Medical Technology Co., Ltd. Recruiting since 15 July 2026 at Beijing Tiantan Hospital; 34 participants planned.

  2. 02

    BCIFlex releases 1000-channel invasive flexible brain-computer interface system (opens in a new tab)

    Independent reportingVCBeat31 Mar 2026Checked against source 6 Oct 2026

    Chinese health-industry trade press in English, reporting the company's launch. Gives 560 to 1,024 channels, a fully implanted design, a first implantation in 2025 and a registration trial planned for 2026. It does not say where the electrodes are placed.

  3. 03

    BCIFlex secures over ¥300 million in Series A funding (opens in a new tab)

    Independent reportingG-MedTech12 Aug 2025Checked against source 6 Oct 2026

    Trade press. Gives the round as over RMB 300 million (US$42 million), the lead investors, Beijing and the founding in 2022.

  4. 04

    China's brain-computer interface sector achieves accelerating progress (opens in a new tab)

    Independent reportingState Council Information Office of China17 Jul 2026Source identified, not opened

    Found through search. The page could not be opened: its certificate did not match its address. State media, reporting a company's own presentation.